Evidence map›Paper›PMID 28698846›Full record

ArticleBlood research2017

Evaluation of the role of

Mohammad Mehdi Akbarin, Abbas Shirdel, Alireza Bari, Seyedeh Tahereh Mohaddes, Houshang Rafatpanah, Ehsan Ghayour Karimani, Kobra Etminani, Amin Golabpour, Reza Torshizi

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. TAX and HBZ: hFc Ɣ 1 proteins as targets for passive immunotherapy.Iranian journal of basic medical sciences · 2022
    Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Mohammad Mehdi AkbarinInflammation and Inflammatory Diseases Research Center, Faculty of Medicine, Mashhad University of Medical sciences, Mashhad, Iran.
Abbas ShirdelHematology Department, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciencess, Mashhad, Iran.
Alireza BariHematology Department, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciencess, Mashhad, Iran.
Seyedeh Tahereh MohaddesHematology Department, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciencess, Mashhad, Iran.
Houshang RafatpanahInflammation and Inflammatory Diseases Research Center, Faculty of Medicine, Mashhad University of Medical sciences, Mashhad, Iran.
Ehsan Ghayour KarimaniMolecular Diagnostic Unit, Research and Education Department, Razavi Hospitals, Mashhad, Iran.
Kobra EtminaniDepartment of Medical Informatics, Molecular Medicine Department, Faculty of Medicine, Mashhad University of Medical sciences, Mashhad, Iran.
Amin GolabpourDepartment of Medical Informatics, Molecular Medicine Department, Faculty of Medicine, Mashhad University of Medical sciences, Mashhad, Iran.
Reza TorshiziDepartment of Modern Sciences and Technologies, Molecular Medicine Department, Faculty of Medicine, Mashhad University of Medical sciences, Mashhad, Iran.
Mashhad University of Medical Sciences · IRGhaem Hospital · IREmam Reza Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdult T-cell leukemia/lymphoma (ATLL) is an aggressive malignancy with very poor prognosis and short survival, caused by the human T-lymphotropic virus type-1 (HTLV-1). The HTLV-1 biomarkers trans-activator x (TAX) and HTLV-1 basic leucine zipper factor (HBZ) are main oncogenes and life-threatening elements. This study aimed to assess the role of the

methodsForty-three HTLV-1-infected individuals, including 18 asymptomatic carriers (AC) and 25 ATLL patients (ATLL), were evaluated between 2011 and 2015. The mRNA expression of

resultsSignificant differences in the mean expression levels of

conclusionThe HTLV-1 PVL and expression of

Indexed as

ATLLHBZHTLV-1Proviral loadTAX

Identifiers

PMID28698846
PMCPMC5503887
OpenAlexW2729439867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.